Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04476901 · ClinicalTrials.gov registry record · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
A Phase 2 study of Non-ischemic Dilated Cardiomyopathy, sponsored by Joshua M Hare.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 4
- Study locations
NCT04476901: Recruiting Phase 2 study of Non-ischemic Dilated Cardiomyopathy, sponsored by Joshua M Hare.
NCT04476901 is a Phase 2 study of Non-ischemic Dilated Cardiomyopathy that is actively recruiting participants, run by Joshua M Hare. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04476901, a Phase 2 study of Non-ischemic Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Joshua M Hare.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.
Primary Outcome
Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL allogeneic human mesenchymal stem cells (hMSCs)
Study Locations (4)
California
- Stanford University - Stanford
Florida
- University of Miami Miller School of Medicine - Miami
Kentucky
- University of Louisville - Louisville
Texas
- Texas Heart Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT04476901 shows while recruiting
NCT04476901 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Non-ischemic Dilated Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04476901 reports a single indexed study location in California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04476901 about?
NCT04476901 is a clinical study titled "Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy". The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.
What is the current status of trial NCT04476901?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2021-05-07. Estimated completion is 2025-12.
What conditions does trial NCT04476901 study?
This clinical trial studies the following conditions: Non-ischemic Dilated Cardiomyopathy.
What interventions are being tested in trial NCT04476901?
The interventions under investigation include: Placebo (OTHER), allogeneic human mesenchymal stem cells (hMSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04476901?
This trial is sponsored by Joshua M Hare, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04476901 being conducted?
This trial has 4 study locations across California, Florida, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04476901's enrollment target sits among peer trials
136 527th of 2000 higher than 1,470 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
- NCT04869059 · 136 participants · NA
Treating Mild Traumatic Brain Injury With High Definition Transcranial Direct Current Stimulation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI